Stem definition | Drug id | CAS RN |
---|---|---|
humanized origin | 5083 | 1143503-69-8 |
Molecule | Description |
---|---|
Synonyms:
|
A humanized anti-interleukin 17 monoclonal antibody used for the treatment of PSORIASIS.
|
Dose | Unit | Route |
---|---|---|
2.90 | mg | P |
None
Date | Agency | Company | Orphan |
---|---|---|---|
July 4, 2016 | PMDA | Eli Lilly Japan | |
Feb. 25, 2016 | EMA | ||
March 22, 2016 | FDA | ELI LILLY AND CO |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Injection site erythema | 471.16 | 30.21 | 230 | 7072 | 74197 | 46604563 |
Injection site reaction | 437.56 | 30.21 | 191 | 7111 | 47658 | 46631102 |
Injection site pain | 413.64 | 30.21 | 238 | 7064 | 106914 | 46571846 |
Injection site swelling | 384.93 | 30.21 | 166 | 7136 | 40161 | 46638599 |
Psoriasis | 378.21 | 30.21 | 202 | 7100 | 78402 | 46600358 |
Therapy cessation | 298.55 | 30.21 | 123 | 7179 | 26506 | 46652254 |
Therapy interrupted | 196.51 | 30.21 | 71 | 7231 | 10720 | 46668040 |
Injection site pruritus | 151.89 | 30.21 | 88 | 7214 | 39655 | 46639105 |
Injection site warmth | 148.71 | 30.21 | 62 | 7240 | 13710 | 46665050 |
Injection site urticaria | 139.80 | 30.21 | 57 | 7245 | 11910 | 46666850 |
Injection site rash | 109.02 | 30.21 | 52 | 7250 | 15761 | 46662999 |
COVID-19 | 106.90 | 30.21 | 54 | 7248 | 18521 | 46660239 |
Ear infection | 87.96 | 30.21 | 51 | 7251 | 22962 | 46655798 |
Drug ineffective | 77.27 | 30.21 | 256 | 7046 | 677582 | 46001178 |
Sinusitis | 73.87 | 30.21 | 96 | 7206 | 129672 | 46549088 |
Psoriatic arthropathy | 73.37 | 30.21 | 54 | 7248 | 36325 | 46642435 |
Nasopharyngitis | 66.84 | 30.21 | 100 | 7202 | 153898 | 46524862 |
Urticaria | 60.59 | 30.21 | 83 | 7219 | 117809 | 46560951 |
Product dose omission issue | 60.07 | 30.21 | 100 | 7202 | 168420 | 46510340 |
Tooth infection | 54.42 | 30.21 | 30 | 7272 | 12256 | 46666504 |
Pharyngitis streptococcal | 49.81 | 30.21 | 25 | 7277 | 8443 | 46670317 |
Injection site mass | 48.78 | 30.21 | 30 | 7272 | 15010 | 46663750 |
Injection site bruising | 48.49 | 30.21 | 42 | 7260 | 35594 | 46643166 |
Inappropriate schedule of product administration | 41.52 | 30.21 | 51 | 7251 | 64962 | 46613798 |
SARS-CoV-2 test positive | 40.07 | 30.21 | 14 | 7288 | 1911 | 46676849 |
Influenza | 37.27 | 30.21 | 57 | 7245 | 89213 | 46589547 |
Pruritus | 36.16 | 30.21 | 101 | 7201 | 242251 | 46436509 |
Surgery | 35.31 | 30.21 | 32 | 7270 | 28753 | 46650007 |
Fungal infection | 34.62 | 30.21 | 32 | 7270 | 29488 | 46649272 |
Rash | 33.65 | 30.21 | 127 | 7175 | 356385 | 46322375 |
Infection | 33.29 | 30.21 | 68 | 7234 | 133524 | 46545236 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Psoriasis | 391.86 | 29.61 | 170 | 4479 | 42336 | 29905493 |
Injection site pain | 345.16 | 29.61 | 141 | 4508 | 30169 | 29917660 |
Injection site reaction | 287.45 | 29.61 | 94 | 4555 | 10666 | 29937163 |
Injection site erythema | 283.43 | 29.61 | 99 | 4550 | 13735 | 29934094 |
Therapy cessation | 215.92 | 29.61 | 83 | 4566 | 15054 | 29932775 |
Injection site swelling | 188.02 | 29.61 | 65 | 4584 | 8715 | 29939114 |
Drug ineffective | 101.60 | 29.61 | 185 | 4464 | 340202 | 29607627 |
Therapy interrupted | 94.83 | 29.61 | 33 | 4616 | 4496 | 29943333 |
Injection site rash | 90.65 | 29.61 | 30 | 4619 | 3509 | 29944320 |
Nasopharyngitis | 90.40 | 29.61 | 74 | 4575 | 58775 | 29889054 |
Injection site pruritus | 88.04 | 29.61 | 33 | 4616 | 5559 | 29942270 |
COVID-19 | 69.66 | 29.61 | 40 | 4609 | 17838 | 29929991 |
Ear infection | 69.22 | 29.61 | 30 | 4619 | 7344 | 29940485 |
Sinusitis | 59.85 | 29.61 | 46 | 4603 | 33299 | 29914530 |
Pruritus | 55.09 | 29.61 | 79 | 4570 | 118125 | 29829704 |
Injection site warmth | 53.13 | 29.61 | 17 | 4632 | 1785 | 29946044 |
Infection | 51.60 | 29.61 | 62 | 4587 | 78012 | 29869817 |
Product dose omission issue | 48.27 | 29.61 | 65 | 4584 | 91566 | 29856263 |
Influenza | 47.36 | 29.61 | 45 | 4604 | 43353 | 29904476 |
Injection site bruising | 44.33 | 29.61 | 22 | 4627 | 7316 | 29940513 |
Rash | 43.11 | 29.61 | 93 | 4556 | 191796 | 29756033 |
Insurance issue | 42.44 | 29.61 | 12 | 4637 | 826 | 29947003 |
Injection site mass | 39.56 | 29.61 | 18 | 4631 | 4935 | 29942894 |
Wrong technique in device usage process | 36.58 | 29.61 | 11 | 4638 | 940 | 29946889 |
Inappropriate schedule of product administration | 35.57 | 29.61 | 37 | 4612 | 39691 | 29908138 |
Arthralgia | 34.16 | 29.61 | 69 | 4580 | 135722 | 29812107 |
Knee operation | 32.66 | 29.61 | 11 | 4638 | 1355 | 29946474 |
Fungal infection | 31.72 | 29.61 | 22 | 4627 | 13578 | 29934251 |
Psoriatic arthropathy | 31.03 | 29.61 | 23 | 4626 | 15738 | 29932091 |
Cutaneous lymphoma | 30.95 | 29.61 | 6 | 4643 | 76 | 29947753 |
Source | Code | Description |
---|---|---|
ATC | L04AC13 | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS IMMUNOSUPPRESSANTS IMMUNOSUPPRESSANTS Interleukin inhibitors |
MeSH PA | D003879 | Dermatologic Agents |
FDA MoA | N0000191494 | Interleukin-17A Antagonists |
FDA EPC | N0000191495 | Interleukin-17A Antagonist |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Ankylosing spondylitis | indication | 9631008 | DOID:7147 |
Plaque psoriasis | indication | 200965009 |
None
None
None
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
Interleukin-17A | Cytokine | ANTIBODY BINDING | DRUG LABEL | DRUG LABEL |
ID | Source |
---|---|
D10071 | KEGG_DRUG |
4035606 | VANDF |
C3489764 | UMLSCUI |
CHEMBL1743034 | ChEMBL_ID |
DB11569 | DRUGBANK_ID |
C549079 | MESH_SUPPLEMENTAL_RECORD_UI |
7541 | IUPHAR_LIGAND_ID |
9467 | INN_ID |
BTY153760O | UNII |
1745099 | RXNORM |
31578 | MMSL |
d08425 | MMSL |
016752 | NDDF |
724037000 | SNOMEDCT_US |
763603002 | SNOMEDCT_US |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
TALTZ | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0002-1445 | INJECTION, SOLUTION | 80 mg | SUBCUTANEOUS | BLA | 30 sections |
TALTZ | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0002-7724 | INJECTION, SOLUTION | 80 mg | SUBCUTANEOUS | BLA | 30 sections |